That is the claim by Kaneka Pharma Europe, which developed the novel food ingredient, and has secured extended use approval from the EC.
Besides being used in food supplements and beverages based on milk, yogurt, fruit and vegetables, as accredited by its Novel Food status since 2011, Glavonoid can now also be applied in foods intended for medical purposes and energy-restricted diets for weight reduction.
Kaneka says that Glavenoid has been shown to both increase the body’s fat burning ability and to decrease fat development. In addition, it says, Glavonoid may also optimise cholesterol and blood glucose levels.
“Promising market potential”
Peter Lambrechts, business development manager at Kaneka’s Quality of Life division, who managed the approval process, said: “With visceral fat being the main risk factor for the development of metabolic syndromes and other chronic diseases such as cardiovascular illnesses, we see extremely promising market potential here.
“The new regulatory status for Glavonoid paves the way for manufacturers to create new products targeting markets such as weight management and body shaping.”